​

GeneDx (WGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WGS Stock Forecast

GeneDx (WGS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $42.50, with a high of $70.00 and a low of $21.00. This represents a -53.69% decline from the last price of $91.78.

- $19 $38 $57 $76 $95 High: $70 Avg: $42.5 Low: $21 Last Closed Price: $91.78

WGS Stock Rating

GeneDx stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

WGS Price Target Upside V Benchmarks

TypeNameUpside
StockGeneDx-53.69%
SectorHealthcare Stocks 19.91%
IndustryHealthcare Information Services Stocks 24.43%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$49.67
Last Closing Price$91.78$91.78$91.78
Upside/Downside---45.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25-51--6
Jun, 25-52--7
May, 25-33--6
Apr, 25-33--6
Mar, 25-33--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Bill BonelloCraig-Hallum$70.00$58.0020.69%-23.73%
Aug 27, 2024Brandon CouillardWells Fargo$34.00$35.35-3.82%-62.95%
Jul 31, 2024Mark MassaroBTIG$45.00$30.1349.35%-50.97%
Jul 10, 2024Bill BonelloCraig-Hallum$43.00$29.8144.25%-53.15%
Jun 26, 2024Mark MassaroBTIG$35.00$26.1933.64%-61.87%
Jun 03, 2024Tycho PetersonJefferies$21.00$19.617.09%-77.12%
Apr 30, 2024Mark MassaroBTIG$19.00$11.0072.73%-79.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 30, 2025GuggenheimBuyBuyhold
May 15, 2025GuggenheimBuyinitialise
Jan 07, 2025Cowen & Co.BuyBuyhold
Oct 29, 2024Wells FargoEqual-WeightEqual-Weighthold
Oct 29, 2024BTIGBuyBuyhold
Oct 24, 2024Craig-HallumBuyBuyhold
Aug 27, 2024Wells FargoEqual-Weightinitialise
Jul 31, 2024Craig-HallumBuyBuyhold
Jul 31, 2024Cowen & Co.BuyBuyhold
Jul 31, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-74.93$-53.63$-7.23$-1.94---
Avg Forecast$-34.54$-29.04$-5.35$-0.27$0.55$1.46$2.68
High Forecast$-34.00$-28.74$-5.26$-0.26$0.56$2.17$2.75
Low Forecast$-35.31$-29.45$-5.49$-0.27$0.54$0.74$2.63
Surprise %116.94%84.68%35.14%618.52%---

Revenue Forecast

$150M $220M $290M $360M $430M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$212.19M$234.69M$202.57M$305.45M---
Avg Forecast$203.77M$244.28M$192.76M$290.22M$338.77M$398.42M$476.30M
High Forecast$207.25M$246.90M$196.45M$295.78M$345.27M$406.06M$485.43M
Low Forecast$201.34M$242.35M$190.23M$286.41M$334.33M$393.20M$470.05M
Surprise %4.14%-3.92%5.09%5.25%---

Net Income Forecast

$-900M $-700M $-500M $-300M $-100M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-245.39M$-548.98M$-175.77M$-52.29M---
Avg Forecast$-839.74M$-706.04M$-130.66M$-6.47M$13.36M$35.41M$65.16M
High Forecast$-826.71M$-698.78M$-127.93M$-6.33M$13.64M$52.75M$66.78M
Low Forecast$-858.41M$-715.90M$-133.39M$-6.60M$13.08M$18.08M$64.05M
Surprise %-70.78%-22.25%34.52%708.38%---

WGS Forecast FAQ

Is GeneDx stock a buy?

GeneDx stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GeneDx is a favorable investment for most analysts.

What is GeneDx's price target?

GeneDx's price target, set by 9 Wall Street analysts, averages $42.5 over the next 12 months. The price target range spans from $21 at the low end to $70 at the high end, suggesting a potential -53.69% change from the previous closing price of $91.78.

How does GeneDx stock forecast compare to its benchmarks?

GeneDx's stock forecast shows a -53.69% downside, underperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the healthcare information services stocks industry (24.43%).

What is the breakdown of analyst ratings for GeneDx over the past three months?

  • July 2025: 0% Strong Buy, 83.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 0% Strong Buy, 71.43% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is GeneDx’s EPS forecast?

GeneDx's average annual EPS forecast for its fiscal year ending in December 2025 is $0.55, marking a -128.35% decrease from the reported $-1.94 in 2024. Estimates for the following years are $1.46 in 2026, and $2.68 in 2027.

What is GeneDx’s revenue forecast?

GeneDx's average annual revenue forecast for its fiscal year ending in December 2025 is $338.77M, reflecting a 10.91% increase from the reported $305.45M in 2024. The forecast for 2026 is $398.42M, and $476.3M for 2027.

What is GeneDx’s net income forecast?

GeneDx's net income forecast for the fiscal year ending in December 2025 stands at $13.36M, representing a -125.56% decrease from the reported $-52.286M in 2024. Projections indicate $35.41M in 2026, and $65.16M in 2027.